Literature DB >> 19336464

The retina in Parkinson's disease.

Neil K Archibald1, Michael P Clarke, Urs P Mosimann, David J Burn.   

Abstract

As a more complete picture of the clinical phenotype of Parkinson's disease emerges, non-motor symptoms have become increasingly studied. Prominent among these non-motor phenomena are mood disturbance, cognitive decline and dementia, sleep disorders, hyposmia and autonomic failure. In addition, visual symptoms are common, ranging from complaints of dry eyes and reading difficulties, through to perceptual disturbances (feelings of presence and passage) and complex visual hallucinations. Such visual symptoms are a considerable cause of morbidity in Parkinson's disease and, with respect to visual hallucinations, are an important predictor of cognitive decline as well as institutional care and mortality. Evidence exists of visual dysfunction at several levels of the visual pathway in Parkinson's disease. This includes psychophysical, electrophysiological and morphological evidence of disruption of retinal structure and function, in addition to disorders of 'higher' (cortical) visual processing. In this review, we will draw together work from animal and human studies in an attempt to provide an insight into how Parkinson's disease affects the retina and how these changes might contribute to the visual symptoms experienced by patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336464     DOI: 10.1093/brain/awp068

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  109 in total

1.  Absence of DJ-1 causes age-related retinal abnormalities in association with increased oxidative stress.

Authors:  Vera L Bonilha; Brent A Bell; Mary E Rayborn; Ivy S Samuels; Anna King; Joe G Hollyfield; Chengsong Xie; Huaibin Cai
Journal:  Free Radic Biol Med       Date:  2017-01-11       Impact factor: 7.376

2.  Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.

Authors:  Isabel Ortuño-Lizarán; Thomas G Beach; Geidy E Serrano; Douglas G Walker; Charles H Adler; Nicolás Cuenca
Journal:  Mov Disord       Date:  2018-05-08       Impact factor: 10.338

3.  Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease.

Authors:  Esther Cubo; María Jesús López Peña; Elio Diez-Feijo Varela; Olga Pérez Gil; Pablo Garcia Gutierrez; Elena Araus González; Rosa Prieto Tedejo; Natividad Mariscal Pérez; Diana Armesto
Journal:  J Neural Transm (Vienna)       Date:  2014-02       Impact factor: 3.575

Review 4.  Cellular-Scale Imaging of Transparent Retinal Structures and Processes Using Adaptive Optics Optical Coherence Tomography.

Authors:  Donald T Miller; Kazuhiro Kurokawa
Journal:  Annu Rev Vis Sci       Date:  2020-07-01       Impact factor: 6.422

Review 5.  Protein misfolding and retinal degeneration.

Authors:  Radouil Tzekov; Linda Stein; Shalesh Kaushal
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-11-01       Impact factor: 10.005

6.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

Review 7.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

Review 8.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

Review 9.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

10.  The effects of early diabetes on inner retinal neurons.

Authors:  Erika D Eggers; Teresia A Carreon
Journal:  Vis Neurosci       Date:  2020-09-16       Impact factor: 3.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.